News Brief: Avalon GloboCare Corp.

News Brief: Avalon GloboCare Corp.

Tuesday, September 5, 2023

Freehold, N.J. based Avalon GloboCare Corp. (NASDAQ: ALBT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The publication may be accessed through the USPTO’s publicly available Searchable Databases via the Internet at www.uspto.gov.

According to the release, the patent covers the composition of matter and methodology for multiple novel QTY-Code modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).

The “QTY Code” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, greatly enhancing the solubility of designer peptides and proteins, therefore potentially expanding the repertoire of selected therapeutic targets against cancers and other diseases.

Avalon GloboCare Corp. is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services.  

Avalon shares are trading up 23 cents at $1.23


Other Penny Stock Movers

Canadian Manufacturing and Wholesale Sales Point to Weakening Economy and Raise Possibilities of Rate Cuts
Drill Less, Extract More: This Just Announced Merger Unlocks Profits
100,000,000 Euro Commitment Sends Shares of this MicroCap Hydrogen Automaker Soaring
Most Popular
FREE Newsletter


Back to Top